Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 126   

Articles published

NVO 58.96 +0.68 (1.17%)
price chart
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate-Palmolive ...
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons' Renaissance Technologies, one of the best performing firms in the sector.
Companies That Offer High Returns: Novo Nordisk A/S (ADR) (NYSE:NVO ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products.
Top Healthcare Stocks for 2015: Novo Nordisk A/S (ADR) (NYSE:NVO), Hologic ...
The most recent price of Novo Nordisk A/S (ADR) (NYSE:NVO), is now at a discount to the 12-month high of $58.21 hit on Jun 11, 2015.
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis Is ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »